Ad is loading...
MENU

AIM Stock AIM ImmunoTech (AIM, $0.21) Stochastic Oscillator left the oversold zone on November 21, 2024

A.I.dvisor
at Tickeron.com
Loading...
AIM - AIM ImmunoTech
Stochastic signal
Bullish Trend
Odds of UP Trend
Tickeron
Stochastic signal
Price: $0.2117
Daily change: +$0.0117 (+5.85%)
Daily volume: 773.1K
Capitalization: $13.5M
Industry: Biotechnology
This is a signal that AIM's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options. A.I.dvisor identified 72 similar cases where AIM's stochastic oscillator exited the oversold zone, and of them led to successful outcomes. Odds of Success:

AIM in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 19, 2024

AIM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 38 cases where AIM's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AIM's RSI Indicator exited the oversold zone, of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 72 cases where AIM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where AIM advanced for three days, in of 212 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 04, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on AIM as a result. In of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for AIM turned negative on November 07, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AIM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for AIM entered a downward trend on November 22, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.596) is normal, around the industry mean (13.913). P/E Ratio (0.000) is within average values for comparable stocks, (89.373). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.810). AIM has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (57.803) is also within normal values, averaging (222.803).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. AIM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AIM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
AIM
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
2117 SW Highway 484
Phone
+1 352 448-7797
Employees
28
Web
https://www.aimimmuno.com